LYSOGENE is a pioneering biotechnology company in the field of gene therapy targeting severe genetic pathologies of the central nervous system in children.
LYSOGENE is the only biotechnology company in the world that is specialised in the development of intracerebral gene therapy aimed at treating pathologies affecting the central nervous system, which is the main cause of neuro-degenerative disease mortality in children.
LYSOGENE was founded in 2009 & is based in Paris, Ile-de-France, France with an additional office in Cambridge. Massachusetts.
LYSOGENE is actively expanding its pipeline to additional genetic diseases with high unmet medical needs. Currently, the Company is lauching its new gene therapy translational program LYS-XXX. LYS-XXX targets a severe monogenic indication with strong CNS involvement. The company aims to translate LYS-XXX to phase I/II clinical stage in EU and US no later than 2016.
LYSOGENE is backed by Sofinnova Ventures & Novo Seeds. The company went public on 10 February 2017.